Forskolin

製品コードS2449 別名:Coleonol

Forskolin化学構造

分子量(MW):410.5

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.

サイズ 価格(税別)  
JPY 23240.00
JPY 18260.00
JPY 44820.00
JPY 61420.00
JPY 94620.00

カスタマーフィードバック(2)

  • Eur J Cancer 2014 50(7), 1310-20. Forskolin purchased from Selleck.

    Measurement of cAMP accumulation in INS-1 cells. (A) INS-1, or (B) INS-1 transfected with murine GPR109A for 24 h, or (C) INS-1 transfected with human GPR109A for 24 h were incubated in DMEM (2.5 mM glucose) media with or without PTX (100 ng/ml) for 24 h. Cells were then incubated in KRB supplemented with 2.5 mM glucose, 500 μM IBMX, 10 μM forskolin, and with/without 10 or 100 μM NA for 1 h. After lysis with HCl (0.1 M), cells were sonicated and spun. The supernatants were saved for cAMP measurement by ELISA. (D) Reduction of cAMP accumulation in INS-1 and INS-1 cells transfected with GPR109A in the presence of 10 or 100 μM NA. White bar: INS-1 cells, grey bar: INS-1 cells transfected with murine GPR109A; black bar: INS-1 cells transfected with human GPR109A. (∗ and #p < 0.05, ∗ and ##p < 0.001). (n = 5).

    Gen Comp Endocrinol, 2016, 237:98-108. Forskolin purchased from Selleck.

製品安全説明書

cAMP阻害剤の選択性比較

生物活性

製品説明 Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.
ターゲット
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
体外試験

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 NIHR[mpHfW6ldHnvckBCe3OjeR?= M1GyelExKM7:TR?= M2iyNFYhcA>? MV;pcoNz\WG|ZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJI93\XKneIDy[ZN{\WRiS1zIUFMh[XRiU{SzNy=> M3XiUlI3PDN3NEm4
Mo-DCs MXfGeY5kfGmxbjDBd5NigQ>? NXLZOppXPTBizszN NXLXeZBxOjUkgJno MnzJdJJwdW:2ZYOgTWwuOjNicILv[JVkfGmxbjDpckB1cGVic4Xw[ZJv[XSjboSgc4Yhgnmvb4PhckB{fGmvdXzheIVlKE2xLVTDd:Kh MnPsNlY1OTJ7NEi=
RBMECs  NYLERYxETnWwY4Tpc44hSXO|YYm= NFfPdnE2yqEQvF2= MnvyNeKhcA>? NGDXTWljdG:la4OgeIhmKFKjY{GgbY5i[3SrdnH0bY9vKGmwZIXj[YQh[nliRV3BVE1KUQ>? NHH6cpEzPjN3OECzPS=>
INA-6 NYjIWYJtS2WubDDWbYFjcWyrdImgRZN{[Xl? MkDUNE0yODBizszN MojFO|LjiImq M{nOcolv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 NH[wOVczPjNyNk[yOC=>
OPM-2 MWnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUC3NGo2OC1zMECg{txO NHvMU4Y4OuLCiXi= M{nERYlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 MVKyOlMxPjZ{NB?=
U266 M3z4cWNmdGxiVnnhZoltcXS7IFHzd4F6 M3\3d|AuOTByIN88US=> MVW3NwKBkWh? MnjobY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= M2nsc|I3OzB4NkK0
H929 NV3zN4NbS2WubDDWbYFjcWyrdImgRZN{[Xl? M4rVc|AuOTByIN88US=> M{HGT|cz6oDLaB?= NETMfodqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> M4fHZ|I3OzB4NkK0
RPMI 8226 NE\pdFdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NU\JeoY4OC1zMECg{txO M3PkOVcz6oDLaB?= NHzCW5ZqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> MoTzNlY{ODZ4MkS=
MDCK  NWPV[lBwTnWwY4Tpc44hSXO|YYm= MV6xNEDDvU1? MnPpNlQhcA>? NIHte2hFVVOR Ml7heZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhXEeILd8yNUBidmRiQ2THSuKh MXiyOlIxOjN3Mh?=
MDCK  NFjlUFZHfW6ldHnvckBCe3OjeR?= MUmxNEDDvU1? NFKwXJgzPCCq MlHkSG1UVw>? MVnpcohq[mm2czD0bIUhcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gSm4h[2G3c3XkJIJ6KFSJRj5OtlE> M1THPVI3OjB{M{Wy
Spinal cords  M4jvcWZ2dmO2aX;uJGF{e2G7 NHXqOnMyyqEQvF2= MlLDN|AhdWmw MXvzeIlufWyjdHXzJINCVVBibHX2[Yx{ MWSyOlEzPjl{Nh?=
BeWo  NXrzNHl[TnWwY4Tpc44hSXO|YYm= M4jwZlI26oDLzszN MX2yOE81QC95MjDo M4jmRoxm[WS|IITvJIFvKGmwY4LlZZNmKGmwIITo[UBmgHC{ZYPzbY9vKG:oIH;0bIVzKG[3c3nvckBu[XKtZYLz MlH6NlYxPTN3NEm=
bovine oocytes NWf6PIlOTnWwY4Tpc44hSXO|YYm= MXGxNFDDqM7:TR?= M1jnOFEzyqCq MlzDbY5pcWKrdIOgeIhmKGWoZnXjeEBw\iCQUGDBJIFv\C:xcjDOVHBEKHSxIIP0bY12dGG2ZTDy[ZN2dXC2aX;uJI9nKG2naX;zbZM> M3PHNFI3ODVzNkGx
Caco-2  NGSxTXNHfW6ldHnvckBCe3OjeR?= MU[wMlEwOS9zMDFOwG0> MX6yNOKhdWmw MoLmbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJIlvfHKjY3XscJVt[XJiY1HNVEBt\X[nbIO= M{L0SFI3ODR7MUCy
Caco-2  NYrqWoF[TnWwY4Tpc44hSXO|YYm= MVKwMlEwOS9zMDFOwG0> MmXONlQhcA>? M1ixRolv[3KnYYPld{BOWlB{IIDyc5RmcW5ibHX2[Yw> NFLZeoszPjB2OUGwNi=>
AML-12  M3fLemZ2dmO2aX;uJGF{e2G7 MVOyNEDPxE1? NVvGfZZZOyCq Mn7zeZBz\We3bHH0[ZMhfGinIIDoc5NxcG:{eXzheIlwdiCuZY\lcJMh[XRiVHjyMVQyOSCjbnSgV4VzNTR7Mx?= NW\xb5VjOjZyNEi5PFU>
AML-12  NHX4NpZHfW6ldHnvckBCe3OjeR?= MlyyNlAh|ryP NHnGSIgyNThiaB?= M3XZRYlv[3KnYYPld{BodHWlb4PlJJBzd2S3Y4Tpc44> NE\hd3kzPjB2OEm4OS=>
AML-12  NWXw[I5mTnWwY4Tpc44hSXO|YYm= MmDyNlAh|ryP NF7IcVM{KGh? NXX6RZV[fXBvcnXneYxifGW|wrDQ[4My[S{EoGDldINsNCCjbnVCpGc3eGQEoH3SUmEhdGW4ZXzz MVSyOlA1QDl6NR?=
AML-12  MWjGeY5kfGmxbjDBd5NigQ>? MkfxNlAh|ryP NHK3OZo{KGh? MVvpcoR2[2W|IITo[UBl\XCqb4PwbI9zgWyjdHnvckBw\iCFUmTDNuKh M2DEZVI3ODR6OUi1
RBMECs NHzOcHdHfW6ldHnvckBCe3OjeR?= NFLzUFg2yqEQvF2= Mn7JNUBp NFvtTWxqdmirYnn0d{BGVUGSLVnJMYlv\HWlZXSgbY5i[3SrdnH0bY9vKG:oIGLhdFHDqA>? NVnqRW1DOjZyNES2OlM>
EndoC-βH1 NEPrVZlHfW6ldHnvckBCe3OjeR?= M1fmd|XDqM7:TR?= MnLzNUBp M4XGTpBwfGWwdHnheIV{KGeudXPvd4UucW6mdXPl[EBqdnO3bHnuJJNm[3KndHnvckBqdiC2aHWgdJJme2WwY3Wgc4Yh\2y3Y3;z[S=> MkHKNlYxOjh3NkK=
EndoC-βH1 Mle5SpVv[3Srb36gRZN{[Xl? M{O1fFXDqM7:TR?= MXGxJIg> MXzs[YFleyC2bzDhJJN1em:wZzDjRW1RKGmwY4LlZZNm M3LoPVI3ODJ6NU[y
SH-SY5Y MUjGeY5kfGmxbjDBd5NigQ>? M2jFelMxKM7:TR?= M4TrWlMxKG2rbh?= M4i0bWROW09? M3m5VZNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBi[3SrdnH0bY9vKG:oIGDLRS=> NF31XHIzPjB{NUGzOy=>
PC-3 MW\GeY5kfGmxbjDBd5NigQ>? MlPsOFAhyrWP NWTQTXl7OiCq MXjEUXNQ M33qe4xm[WS|IITvJHBROkFiYXP0bZZifGmxbh?= MXGyOlAzOzh|Nh?=
PC-3 NWTlcHk4S2WubDDWbYFjcWyrdImgRZN{[Xl? NVTvdHFGPDBiwsXN NVXRSItbOjRxNEivO|IhcA>? MXPEUXNQ NFT4fVJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgeIlu\SCmZYDlcoRmdnSueR?= M1;XWFI3ODJ|OEO2
SCG NF3yW2dHfW6ldHnvckBCe3OjeR?= M1PC[VIxKM7:TdMg NUXOdFhpTE2VTx?= MUTy[ZZmenOrYnz5JJN2eHC{ZYPz[ZMhUUuYIIfpeIgh[SCLQ{WwJI9nKDJ2LkSg{txO M2G5PFI2QTZ{MUOy
HEK-293 NIq2cZhHfW6ldHnvckBCe3OjeR?= NVf5cG96OzVizszNxsA> NXiwWZZ1TE2VTx?= NVnuVY11cW6mdXPld{BiKGOxboPwbYN2d3W|IPMAoIlv[WO2aY\heIlwduLCnTDv[kB1cGViS4[yMlEh[3W{cnXueC=> M2HjZVI2QTZ{MUOy
SCG NWW5VnFTTnWwY4Tpc44hSXO|YYm= MXuxNFAh|ryPwrC= NFzpT4ZFVVOR MkTYdoVlfWOnczD0bIUh\XilaYThZoltcXS7IH;mJHNETyCwZYXyc45{ MlLBNlU6PjJzM{K=
PCCL3 NH23XZBHfW6ldHnvckBCe3OjeR?= MmXHNVAhyrWP MlL2NlQhcA>? MlfP[Y5p[W6lZYOgSJVQgDJicILvcY91\XJidILhcpNkemmydHnvckBi[3Srdnn0feKh6oDN MXiyOVk3ODl3Nh?=
3T3-L1 preadipocytes NH3uXXdHfW6ldHnvckBCe3OjeR?= NW\tOmM2OTBizszNxsA> NFLnZmgyOiCq NHPPdpRqdmS3Y3XzJGNTTUJicHjvd5Bpd3K7bHH0bY9vKGGwZDDDM2VDWM7{IHX4dJJme3Orb36= M3jpZVI2QTJ6MEW4
H295R  MknxSpVv[3Srb36gRZN{[Xl? MkDZNVDDqM7:TR?= M4[xUVQ5yqCq M3vKWIlv[3KnYYPld{B{fGW{b3nkJI1mfGGkb3zpeIV{KGmwIITo[UBidmS{b3flckwhdWmwZYLhcI8uKGGwZDDncJVkd2OxcoTpZ49q\CCyYYToe4F6ew>? M3nDOVI2QDZ7NUW2
PBMC NYf0dGhkTnWwY4Tpc44hSXO|YYm= NYLNZpg5PTEEoN88US=> NWnWRldMOjUEoHlCpC=> MWrpcohq[mm2czD0bIUhcW6lcnXhd4VlKHOnY4LleIlwdiCxZjDUUmYhcW6mdXPl[EBjgSC2aHWgSHBG NIDt[2kzPTh4NkC3PS=>
GLUTag  NHXLfJFHfW6ldHnvckBCe3OjeR?= M{fWO|Ex6oDLwsXN NGXCV28xNzJxNDDo NHvFfnZ{fGmvdXzheIV{KEeOUD2xJJNm[3KndHnvckBkd3S{ZXH0[YQhf2m2aDDJRm1Z NXfzcI5kOjV6M{K2N|E>
GLUTag  M{jaSWZ2dmO2aX;uJGF{e2G7 NF3hUYEyOOLCidM1US=> NYjGTJVLPCCq MX7pcoNz\WG|ZYOgeIhmKHCFUlXCJIxmfmWuczD3bZRpKHSqZTDJRm1Z Mn7WNlU5OzJ4M{G=
BAECs NXi1RohNTnWwY4Tpc44hSXO|YYm= M17HbFI2KM7:TR?= NYfEfoNCOjRiaB?= MYXlcohidmOnczD0bIUh[WO2aY\heIlwdiCxZjDQVGFT|rFiYomgOUDPxE1icnXzeoVz[XS{b3ysJHQ1UFNuIH;yJFQuWEGS NWXwcVlbOjV5OUi4NlY>
PC12 MoTZSpVv[3Srb36gRZN{[Xl? Ml7iNlXDqM7:TR?= NV\DUFRoPDhiaB?= NGjWfG1i[3SrdnH0[ZMh[0GPUB?= MXeyOVc3QTNyNR?=
GH3 NH\Gc4RHfW6ldHnvckBCe3OjeR?= MnPRNeKh|ryP MWi2MYg> MV3heJRmdnWjdHXzJJRp\SClb4Ly[YxifGmxbjDi[ZR4\WWwIGDSUEBidmRiQn3hcFEh\XiycnXzd4lwdg>? M3X0U|I2PzJ5MEG4
GH3 MnT3SpVv[3Srb36gRZN{[Xl? NX7RUZI3OcLizszN NHX6WpQ3NWh? MlLMbY5lfWOnczDQVmwh[W6mIFLtZYwyNCCkdYSgco91KEOub3PrMEBuWk6DIHX4dJJme3Orb36= Mn7kNlU4OjdyMUi=
BeWo M3fweWZ2dmO2aX;uJGF{e2G7 Mor0NVDjiIsQvF5CpC=> MXK3NkBp NVeyN2ZMTE2VTx?= MVTt[YRq[XSnczDC[XdwKGOnbHyg[Iln\mW{ZX70bYF1cW:w MUiyOVcyOzR{NR?=
oocytes M3zVdGZ2dmO2aX;uJGF{e2G7 MnW1OUDPxE1? NYKy[ZdUOjRiaB?= NGPlSZZifHSnboXheIV{KHKqLXnud5VtcW5iYXP0bY9vKG:wIH;vZ5l1\SCJVlLEJJNq\26rZnnjZY51dHoEoB?= MlrrNlU4ODd6NUS=
SC M1\4NmZ2dmO2aX;uJGF{e2G7 Ml3QNE42KM7:TR?= M2j2clI1KGh? M3;Oc41qdWmla4OgeIhmKGWoZnXjeEBw\iClQV3QJIFv[WyxZ4Ogc44hVzFiYX7kJG1DWCCneIDy[ZN{cW:w MUCyOVcxPTh5NB?=
SC M{O1e2Z2dmO2aX;uJGF{e2G7 MmP1NE42KM7:TR?= NVr0XFZPPzJiaB?= MUPpcoNz\WG|ZYOgZo91cCCNcn;4MVIxKGGwZDDPNUBmgHC{ZYPzbY9vKGmwIHH4c44uemWuYYTl[EBUS3NiYoX0JI9vdHliS4LvfE0zOMLi MoDnNlU4ODV6N{S=
UACC-647  M4H6d2Z2dmO2aX;uJGF{e2G7 NV3sNWp7TE2VTx?= MUTs[YFleyC2bzDhJJJqe2ViaX6gZ2FOWCCuZY\lcJMhMEWFNUFCpF3DqDJyLkO5xsDPxE1r NXL2PIVJOjV5MEOwNlU>
UACC-647  MnvKSpVv[3Srb36gRZN{[Xl? MlW5NVDDqM7:TR?= NWfKTJJFOTVibXnu M4HyRWROW09? MVjpcohq[mm2czDFVmsheGixc4Doc5J6dGG2aX;u NFmxPIszPTdyM{CyOS=>
UACC-647  NEezVlBHfW6ldHnvckBCe3OjeR?= Mk\tNVDDqM7:TR?= MV[xOUBucW5? MUnEUXNQ NIT4OVVqdmO{ZXHz[ZMh\UWIMjDwbI9{eGixconsZZRqd25ibHX2[Yx{yqB? MUWyOVcxOzB{NR?=
SH-SY5Y  NGXzbG9HfW6ldHnvckBCe3OjeR?= NUD4[GJDOTEEoN88US=> MnW2NeKhcMLi NGD5XWtqdmO{ZXHz[ZMhVFWFIHHjeIl3cXS7 NYrNPIY5OjV3OUe0N|M>
SH-SY5Y  MoHtSpVv[3Srb36gRZN{[Xl? NXrBWFVyOTEEoN88US=> NH23d|kyyqCqwrC= NXe4TXhMcW6lcnXhd4V{KEGJQ{GgcXJPSSCuZY\lcC=> MXGyOVU6PzR|Mx?=
hADSCs NWr1cFdDTnWwY4Tpc44hSXO|YYm= MnruOgKBkcL3TR?= NXyxV21OOzBibXnu NIH3eW5qdmO{ZXHz[ZMh[0GPUDDs[ZZmdHN? NHjMcoQzPTV7MUmwPC=>
HEK293  NUnSVWJtTnWwY4Tpc44hSXO|YYm= MUO15qCKyrWP M4j1TVMxKG2rbh?= NFnJVFFqdmO{ZXHz[ZMh[0GPUDDs[ZZmdHN? NFzwbG0zPTV7MUmwPC=>
3T3-L1 NHG4XphHfW6ldHnvckBCe3OjeR?= MV2yMlUwPSEQvF2= NIG2U|UzPCCqwrC= MUXzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCDVFfMJJBzd3SnaX6g[ZhxemW|c3nvckBifCCjbHyg[I9{\XNidHXzeIVl NHHN[nozPTV7MEW5Oy=>
OCI-Ly1  MXTGeY5kfGmxbjDBd5NigQ>? NUWxbFM6PDEEoN88US=> MUCxxsBpyqB? M{m4SmROW09? Mk\VbY5lfWOnczD0bIUhcW6lcnXt[Y51KG:oIHPBUXAh[2:wY3XueJJifGmxboO= NF3yXoUzPTV5NkKyNC=>
OCI-Ly18  NXfjU|lRTnWwY4Tpc44hSXO|YYm= NV;0cGlMPDEEoN88US=> MnXkNeKhcMLi MnO1SG1UVw>? NWrKT4NScW6mdXPld{B1cGViaX7jdoVu\W62IH;mJINCVVBiY3;uZ4VvfHKjdHnvcpM> MYmyOVU4PjJ{MB?=
BeWo M2ntS2Z2dmO2aX;uJGF{e2G7 NX:2OGVTOjEEoNM1US=> NWKxWmZ6PDkEoHi= NHTve29FVVOR NUD2OVNWcW6lcnXhd4V{KHSqZTDkbYZn\XKnboTpZZRqd25ib3[gRoVYdyClZXzsdy=> NFHkcJczPTV4Nke0NC=>
BeWo NXf1folYTnWwY4Tpc44hSXO|YYm= MVqyNOKhyrWP NVmxcnJvPDkEoHi= NV7oTHNCTE2VTx?= MYrpcoNz\WG|ZYOgeIhmKGGmaHXzbY9vKG:oIGTIVE0yKG2xbn;jfZRmew>? NUHKNlYxOjV3Nk[3OFA>
LNCaP  MWLGeY5kfGmxbjDBd5NigQ>? MXSxNOKh|ryP M2\yNFEzKGkEoB?= MoHFSG1UVw>? MXfpcoR2[2W|IHGg[JJidWG2aXOgbY5kemWjc3Wgc4YhS1KHQkGgZYN1cX[rdIm= MXqyOVU1QDB7OR?=
ThGCs  MWLGeY5kfGmxbjDBd5NigQ>? NUmzS5UzOTEkgJtOwG0> M4HLXFTjiIqq NVvjVlFY[XWpbXXueJMhUEmIMVGgcIV3\Wy|IIToZZQhf2W{ZTDzeIlufWyjdHXkJIJ6KEOxQ3yy NFf0cIozPTR|M{CyOy=>
ThGCs  MVHGeY5kfGmxbjDBd5NigQ>? MknjNVDjiIsQvF2= MojZOQKBkmh? M4KyWIlv[3KnYYPld{BEd0OuMj3pcoR2[2WmIFXEUlLDqGenbnWg[ZhxemW|c3nvci=> M1rDUlI2PDN|MEK3
ThGCs  MmDGSpVv[3Srb36gRZN{[Xl? M4fKfVEx6oDMzszN NE[0RXE{KGh? NVjrZ5lncW6qaXLpeJMhfGinIHXm[oVkfCCxZjDINm8zKG:wIFXEUlIhdVKQQR?= NILqdXAzPTR|M{CyOy=>
RBMECs M4HO[2Z2dmO2aX;uJGF{e2G7 MWWwMlA2NzBwNT:1JO69VQ>? NFqyc40xNjJ3IHi= NXfJVXVZcW6lcnXhd4V{KGODTWCgZ49v[2WwdILheIlwdg>? MmDwNlU1OTZ4NUG=
RBMECs NW\Q[GVITnWwY4Tpc44hSXO|YYm= MYe1xsDPxE1? Mm\KNUBp MnjOZoxw[2u|IITo[UBi[3SrdnH0bY9vKG:oIGLoc2EwWk:FSzDpcoR2[2WmIHL5JGVOSVBvSVm= MVuyOVQyPjZ3MR?=
RBMECs NYDuVpAxTnWwY4Tpc44hSXO|YYm= NIfrUZo2yqEQvF2= M{fQVFEhcA>? NV\sPIg1eHKndnXueJMhfGinIFXNRXAuUUlvaX7keYNm\CCWRVXSJJZidHWnIHTlZ5Jm[XOn NX\G[216OjV2MU[2OVE>
RBMECs MlP6SpVv[3Srb36gRZN{[Xl? MlvOOeKh|ryP MVyxJIg> M4WwZ5Bz\X[nboTzJJRp\SCrbnPy[YF{\SCrbjDIVnAh\my3eDDhZ5Jwe3NidHjlJGJVSiCrbnT1Z4VlKGK7IDDFUWFRNUmL MYmyOVQyPjZ3MR?=
RBMECs M1vFZ2Z2dmO2aX;uJGF{e2G7 NXHQN4dtPcLizszN NULLZnkyOSCq MVHpcohq[mm2czD0bIUh\GWlcnXhd4VlKG:oIHHtc5VvfCCxZjDaU{0yKGmwIF3Gd{BqdmS3Y3XkJIJ6KEWPQWCtTWk> M2fMWVI2PDF4NkWx
RBMECs M1j3U2Z2dmO2aX;uJGF{e2G7 NFPjXHM2yqEQvF2= Mn[3NUBp NHLsemlz\X[ncoPld{B1cGViY3jhcodmeyCrbjDaU{0yKGSrc4TybYJ2fGmxbjDz[YVvKHerdHigSW1CWC2LSTD0doVifG2nboS= NVXjOnR3OjV2MU[2OVE>
RBMECs Mn;mSpVv[3Srb36gRZN{[Xl? NF60dFY2yqEQvF2= MnnZNUBp MlexZoxw[2u|IITo[UBGVUGSLVnJMYlv\HWlZXSgZ4hidmenIHnuJG1NSyCyaH;zdIhwenmuYYTpc44> MU[yOVQyPjZ3MR?=
RBMECs NFnaPJdHfW6ldHnvckBCe3OjeR?= M2S0elXDqM7:TR?= MXKxJIg> Mm\CZoxw[2u|IITo[UBi[3SrbjDjfZRwe2unbHX0c44hemWjcoLhcodmdWWwdDDz[YVvKHerdHigSW1CWC2LSTD0doVifG2nboVCpC=> NVHMNWxKOjV2MU[2OVE>
Primary bovine chondrocytes Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjtc402|ryP MUe0PEBp M2LHUJJmfmW{c3XzJJRp\SCrbnjpZol1d3K7IHXm[oVkfCCxZjDj[Yxm[2:6aXKgc44heHKxbHnm[ZJifGmxbjDpckBoem:5dHigdIxifGViY3jvcoRzd2O7dHXz MVSyOVQxPjBzNh?=
EM1  MUDGeY5kfGmxbjDBd5NigQ>? M{LIVlE26oDMzszN NX7qdVB{PDhiaB?= M1Wwe5Jm\HWlZYOgeIhmKGW6cILld5Nqd25ib3dCpGxKTsLib4NCpHBVT1N{wrDpcuKhS0GOUj2gc5LDqEWSQVOyMZNqdGWwY3XkJGVOOSClZXzsd:Kh NFHPRnozPTN5OE[2NS=>
BeWo  NViwfYs6TnWwY4Tpc44hSXO|YYm= MXqyNOKhyrWP NH;jXng1QMLiaNMg NGPSfphFVVORwrC= NEf2Ro1qdmO{ZXHz[ZMhfGinIHLleIEucEOJIILlcIVie2V? NFPONYozPTN4MkK2NC=>
BeWo  M3rISGZ2dmO2aX;uJGF{e2G7 NHXZXIUzOMLiwsXN NYXRfHVFPDkEoHlCpC=> MXHEUXNQyqB? MXXkc5dvemWpdXzheIV{KHSqZTDs[ZZmdCCxZjDUUWVOTjF4 NYDzdlNbOjV|NkKyOlA>
BeWo  M1;PUGZ2dmO2aX;uJGF{e2G7 M1\6clIxyqEEtV2= MnO3OFjDqGkEoB?= MWjEUXNQyqB? Mnjv[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wxib3[gS2NONTF? M3HGdlI2OzZ{Mk[w
granulosa cells NXW5XVJETnWwY4Tpc44hSXO|YYm= Mn7PNVAh|ryP NF60NXkyOi9{NDDo M2TKbYlv[3KnYYPld{B1cGVibHX2[Yx{KG:owrDSS3MzyqCvUl7B NVy3UXRUOjV|M{mxNFU>
granulosa cells MXHGeY5kfGmxbjDBd5NigQ>? NILGToUyOCEQvF2= NV:3ZY1uOTJxMkSgbC=> M1PWZolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIILldI9zfGW{IHHjeIl3cXS7IH\vdkB1cGVibH;u[4V{fCCocnHncYVvfCBq4pkSPFU1NytzOGLHV|IvVFWFKR?= NWnMbVJnOjV|M{mxNFU>
granulosa cells Mn\qSpVv[3Srb36gRZN{[Xl? MkHENVAh|ryP MkfRNlQhcA>? NVXyVJNbcW6lcnXhd4V{KHSqZTDpcpRmdnOrdImgc4YhTE6DL4Dyc5RmcW5iY3;tdIxmgA>? NXLwN2dTOjV|M{mxNFU>
granulosa cells NHPEVmtHfW6ldHnvckBCe3OjeR?= MkPKNVAh|ryP MX[yOEBp MUPpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCUR2OyJJBzd22xdHXyJIFkfGm4aYT5 MWOyOVM{QTFyNR?=
SK-N-AS  MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUHzW3dlOTBizszNxsA> M1\tN|I1NzR6IHi= NVn0R|BC\W6qYX7j[ZMhfGmvZT3k[ZBmdmSnboTsfUBk\WyudXzhdkB3cWGkaXzpeJnDqA>? NUTDUpFOOjV{Nk[wOlM>
SK-N-AS  NGWxXJJHfW6ldHnvckBCe3OjeR?= NYHGRVZCOTBizszNxsA> MmPQNlQhcA>? NFzqWFhqdmO{ZXHz[ZMhfGinIHPBUXAhdGW4ZXzzxsA> NFXUZpYzPTJ4NkC2Ny=>
SK-N-AS  M2XRV2Z2dmO2aX;uJGF{e2G7 NUfIZZVKOTBizszNxsA> MXiyOEBp MnLhbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIN6[2yrbjDENS=> MkW2NlUzPjZyNkO=
SK-N-AS  NF;L[XRHfW6ldHnvckBCe3OjeR?= NUK2dY5LOTBizszNxsA> M2LrfVMxKG2rbh?= MVrpcoR2[2W|IIDoc5NxcG:{eXzheIlwdiCxZjFOtk1k[XSnbnnuJEh{\XJ4N{WpMEBxNUeVS{ROtkApe2W{OTmgZY5lKGOxbnPvcYl1[W62IHjp[4hmeiCuZY\lcJMhd2ZiYXP0bZZmNCC3boDoc5NxcG:{eXzheIVlNCEQsj3jZZRmdmmw NXzRRXRIOjV{Nk[wOlM>
SK-N-AS  MXLGeY5kfGmxbjDBd5NigQ>? M3TZ[VExKM7:TdMg NXfJSIRROTBxM{CvOlAhdWmw NEPjZ4hqdmO{ZXHz[ZMhdGW4ZXzzJI9nKHBvzsKtZ4F1\W6rbjCod4VzPjd3KTDhcoQhcW6mdXPld{Bi[2O3bYXsZZRqd25ib3[gdE3Pui2lYYTlcolvKCi|ZYK2O|UqKGmwIDjw[ZJqMW63Y3zlZZIhemWpaX;udy=> NHu2NWUzPTJ4NkC2Ny=>
SK-N-SH NVW1e5FuS2WubDDWbYFjcWyrdImgRZN{[Xl? NIHodnQyOCEQvF5CpC=> NWK4VIFIPDhiaB?= Mkjv[Y5p[W6lZYOgV2suVi2VSDDu[ZVzd2KuYYP0c41iKGOnbHygeoli[mmuaYT5 Ml;YNlUzPjZyNkO=
HEK‐CFTR NICwb29HfW6ldHnvckBCe3OjeR?= M{PGWVLjiJN3MNMg{txO NGLsVXoxNTF{IH3pci=> MXvEUXNQyqB? NVyycFZscW6mdXPld{BiKGSxc3ZihLBl\XCnbnTlcpQhcW:maXTlJIVn\my3eNMg MVmyOVI3OzJyNx?=
L6 M3rKUGZ2dmO2aX;uJGF{e2G7 M{\F[|QxKML3TR?= MWCyOEBp NX:zb3ZDcW6qaXLpeJMhTE2KMT3pcoR2[2WmIFHreEBi[3SrdnH0bY9v M1fJXlI2OjR5NUWw
MIN6  MYDGeY5kfGmxbjDBd5NigQ>? MXuxNEDPxE4EoB?= NWjlNo03OyCq MWjpcoNz\WG|ZYOgSFMhdVKQQTDlfJBz\XO|aX;u NUD0Wo5WOjV{NEGxNlQ>
ventricular cardiomyocytes  MoDoSpVv[3Srb36gRZN{[Xl? NHLEN4YxNjBzLUGwJO69VQ>? NH3TT5FqdmO{ZXHz[ZMhKGODTWCgZYNkfW23bHH0bY9v NU\5UHl3OjV{MEOxNVM>
ventricular cardiomyocytes  M1PhVGZ2dmO2aX;uJGF{e2G7 NXLFVlFPOC5yMT2xNEDPxE1? NH7tRWpmfm:tZYOgZY4hcW6xdILvdIlkKHKnc4DvcpNmKDF{MNMxNVUmKGGkb4\lJIJie2GuIIfpeIgh[W5iRVO1NOKhd2ZiMj6yJOK2VQ>? M1jkTFI2OjB|MUGz
BeWo  MUfGeY5kfGmxbjDBd5NigQ>? NXXrNFNNOjBiwsXN MWq0PEBp NXiyRphSTE2VT9Mg MVjpcoR2[2W|IHPlcIwh\nW|aX;u NHXSTpczPTF6NES3Oy=>
THP-1  M3vZcmZ2dmO2aX;uJGF{e2G7 M4flNlEwOTBizszN MorMNuKhcA>? M1;VOmROW00EoB?= NGXDTmN{fXCycnXzd4V{KE2FUD2xJJBzd2S3Y4Tpc47DqA>? M3XidFI2OTV2OEiy
Huh-7 M1e2d2Z2dmO2aX;uJGF{e2G7 Ml\tNE0zOCEQvF2= MX6yJIjDqA>? NFHiXY9z\XO3bITzJIlvKGFiZH;z[U1l\XCnbnTlcpQhcW6lcnXhd4UhcW5iYz3NfYMh\XiycnXzd4lwdiCjdDD0bIUheHKxdHXpckBidmRibWLORUBt\X[nbIO= MnTqNlUyODl6M{S=
C6 NGrnVWlHfW6ldHnvckBCe3OjeR?= NYnPOoU3OTBizszNxsA> NUfSb4liOjBibXnu MW\pcoNz\WG|ZYOgZ2FOWCCjY3P1cZVt[XSrb36= NXL0b4hPOjVyNkm0NVc>
SW480 NW\KNFJXTnWwY4Tpc44hSXO|YYm= NFe4b|I1OMLizszN NV;l[oFDPDkEoHi= M1T5V2ROW09? M4fRXYFkfGm4YYTld{BRWDKD M{H2OFI1QTl5NEWx
HT-29  M3;HbWZ2dmO2aX;uJGF{e2G7 MWO0NOKh|ryP MWC0POKhcA>? MYXEUXNQ M3vU[oFkfGm4YYTld{BRWDKD NVfzUHZROjR7OUe0OVE>
SW480 M1KxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe2V4Q1OMLizszN NXTKV2dUOC15MjDo NHTzXGpFVVOR NYPiOHUxcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? Mn7ENlQ6QTd2NUG=
HT-29  Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3lbo5MPDEEoN88US=> NWfFWZl7OC15MjDo NWC5N2FKTE2VTx?= MofVbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> NU\jZZUyOjR7OUe0OVE>
SW480 NXPMXmdYTnWwY4Tpc44hSXO|YYm= MWe0NOKh|ryP NFvQOXo4KGR? M2XmdmROW09? NWT5eVBFemWmdXPld{Bkd2yxbn;zdIhmemViZn;ycYF1cW:wIHPhdIFjcWyrdIpCpC=> MYGyOFk6PzR3MR?=
HT-29  M1P6fmZ2dmO2aX;uJGF{e2G7 M{nmOlQxyqEQvF2= NUnpXnI6PyCm NFLVeFdFVVOR MWjy[YR2[2W|IHPvcI9vd3OyaHXy[UBnd3KvYYTpc44h[2GyYXLpcIl1gcLi MmX4NlQ6QTd2NUG=
SW480 MoPwRZBweHSxc3nzJGF{e2G7 Mm\GOFDDqM7:TR?= NHnEUmc1QMLiaB?= MXXEUXNQ MojHbY5lfWOnczDhckBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMz:3 MYiyOFk6PzR3MR?=
HT-29  MlHTRZBweHSxc3nzJGF{e2G7 NFHoUoM1OMLizszN NYrifI9SPDkEoHi= MXrEUXNQ NX\1OnhQcW6mdXPld{BidiCjY4TpeoF1cW:wIH;mJINie3Cjc3WgN{84 NUOwU5M6OjR7OUe0OVE>
SW480 NX7CSpI2SXCxcITvd4l{KEG|c3H5 MWq0NOKh|ryP M2niXVQ5yqCq NXvM[GtnTE2VTx?= M1GxVIlv\HWlZYOgZ4hidmenczDpckB1cGVicHjvd5Bpd3K7bHH0bY9vKHO2YYT1d{Bw\iCSUELBJJRiemendIO= MoDlNlQ6QTd2NUG=
HT-29  MVjBdI9xfG:|aYOgRZN{[Xl? NWfhU4t1PDEEoN88US=> NXXLbnhDPDkEoHi= NV3HdXdHTE2VTx?= M2flfolv\HWlZYOgZ4hidmenczDpckB1cGVicHjvd5Bpd3K7bHH0bY9vKHO2YYT1d{Bw\iCSUELBJJRiemendIO= M13WelI1QTl5NEWx

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.75 mM)
Ethanol 37 mg/mL (90.13 mM)
Water Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 410.5
化学式

C22H34O7

CAS No. 66575-29-9
保管
in solvent
別名 Coleonol

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00864578 Withdrawn Primary Open Angle Glaucoma|Intraocular Pressure Sooft Italia April 2009 --
NCT00863811 Withdrawn Primary Open Angle Glaucoma|Intraocular Pressure Sooft Italia April 2009 --

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

cAMPシグナル伝達経路

Tags: Forskolinを買う | Forskolin ic50 | Forskolin供給者 | Forskolinを購入する | Forskolin費用 | Forskolin生産者 | オーダーForskolin | Forskolin化学構造 | Forskolin分子量 | Forskolin代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID